Pediatric Microdose and Microtracer Studies Using C-14 in Europe

MA Turner; Miriam Mooij; WHJ Vaes; AD Windhorst; NH Hendrikse; CAJ Knibbe; LT Korgvee; W Maruszak; G Grynkiewicz; RC Garner; Dick Tibboel; BK Park; Saskia de Wildt

doi:10.1002/cpt.163

Pediatric Microdose and Microtracer Studies Using C-14 in Europe

MA Turner, Miriam Mooij, WHJ Vaes, AD Windhorst, NH Hendrikse, CAJ Knibbe, LT Korgvee, W Maruszak, G Grynkiewicz, RC Garner, Dick Tibboel, BK Park, Saskia de Wildt

Pediatric Surgery

Research output: Contribution to journal › Article › Academic › peer-review

21 Citations (Scopus)

Abstract

Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using C-14-labeled probes in Europe to illustrate the strengths and limitations of these approaches.

Original language	Undefined/Unknown
Pages (from-to)	234-237
Number of pages	4
Journal	Clinical Pharmacology & Therapeutics
Volume	98
Issue number	3
DOIs	https://doi.org/10.1002/cpt.163
Publication status	Published - 2015

Access to Document

10.1002/cpt.163

http://hdl.handle.net/1765/90189

Cite this

@article{8f4fb9b301fe4f32ab4334be286bc70d,

title = "Pediatric Microdose and Microtracer Studies Using C-14 in Europe",

abstract = "Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using C-14-labeled probes in Europe to illustrate the strengths and limitations of these approaches.",

author = "MA Turner and Miriam Mooij and WHJ Vaes and AD Windhorst and NH Hendrikse and CAJ Knibbe and LT Korgvee and W Maruszak and G Grynkiewicz and RC Garner and Dick Tibboel and BK Park and {de Wildt}, Saskia",

year = "2015",

doi = "10.1002/cpt.163",

language = "Undefined/Unknown",

volume = "98",

pages = "234--237",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Pediatric Microdose and Microtracer Studies Using C-14 in Europe

AU - Turner, MA

AU - Mooij, Miriam

AU - Vaes, WHJ

AU - Windhorst, AD

AU - Hendrikse, NH

AU - Knibbe, CAJ

AU - Korgvee, LT

AU - Maruszak, W

AU - Grynkiewicz, G

AU - Garner, RC

AU - Tibboel, Dick

AU - Park, BK

AU - de Wildt, Saskia

PY - 2015

Y1 - 2015

N2 - Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using C-14-labeled probes in Europe to illustrate the strengths and limitations of these approaches.

AB - Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using C-14-labeled probes in Europe to illustrate the strengths and limitations of these approaches.

U2 - 10.1002/cpt.163

DO - 10.1002/cpt.163

M3 - Article

SN - 0009-9236

VL - 98

SP - 234

EP - 237

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -